Tetraphase Pharmaceuticals competitors

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Global leader in the oncology pharmaceutical sector having successfully developed, acquired and launched several multi-billion dollar oncology brands across multiple tumor types and therapeutic approaches. Over 3 decades of experience in US and International pharmaceutical development, product strategy, commercialization and business development; and, has cultivated an extensive network with specialists and companies developing new treatment approaches for patients living with cancer. Recently, founded Proventus Health Solutions, a company specializing in helping oncology biotech companies create greater value by integrating development and commercial considerations into a unified approach. A member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO).

With over 25 years’ global experience in product development and commercial leadership across a wide range of therapeutic areas within the biotech and pharmaceutical industry, Frank joined as Chief Executive Officer of Forma Therapeutics in March of 2019. Most recently serving as Senior Vice President, Global Product Strategy and Therapeutic Area Head for the Immunology, Ophthalmology and Infectious Diseases at Genentech, a member of the Roche Group, he was responsible for driving development and commercial strategy for a broad portfolio of molecules in development and for global in-line product sales of more than $11 Billion. Frank’s 13-year career path at Genentech included leadership positions of increasing scope and responsibility for delivering transformative medicines to patients. Previously, as Vice President of the HER2/Breast Cancer Franchise, Frank was responsible for the US P&L for Herceptin®, Perjeta® and Kadcyla®, driving revenues over $4 Billion and launching the first HER2 neoadjuvant indication shaping a new market and treatment paradigm for early HER2 breast cancer patients. As Vice President of Oral Oncolytics, Frank held P&L responsibility for Tarceva®, Zelboraf®, Erivedge® and Xeloda®, advancing personalized medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma, and establishing a new treatment option for patients with advanced basal cell carcinoma. Other roles at Genentech included Franchise Head, Transplant and Tamiflu® as well as Director of Marketing for Ophthalmology and Respiratory. Prior to joining Genentech, Frank spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development. Frank received a bachelor’s degree in chemical engineering from Vanderbilt University and an M.B.A. in Marketing and Finance from the Wharton Graduate School of Business. He previously served on the Board of Directors of the Genentech Foundation.

Jigar Raythatha joined Jounce Therapeutics in December 2012 after a 15 year career in the biotechnology industry in a variety business functions. Most recently, Jigar Raythatha was the head of corporate development of Constellation Pharmaceuticals, Inc. where he was instrumental in securing over $175 million in non-dilutive and equity funding. In addition, Jigar Raythatha negotiated and subsequently led the company's broad epigenetics strategic alliance with Genentech and established Constellation's project management and market development capabilities. Prior to Constellation, Jigar Raythatha worked with Red Abbey Venture Partners, initially as a Kauffman fellow, later as a principal, and finally a venture partner. During his tenure at Red Abbey, Jigar Raythatha led or participated in all of the firm's investments, including Advanced BioHealing (acquired by Shire), Aegerion Pharmaceuticals (IPO), Cogenesys (acquired by Teva), and Stromedix (acquired by Biogen Idec). Previously, Jigar Raythatha has worked with Biogen, Inc. and Pfizer, Inc. in business development and new product planning roles. Jigar Raythatha holds an M.B.A. from Columbia Business School and a B.A. in molecular biology and biochemistry and economics from Rutgers University.